Physician profile
Allan Ocampo
NPI 1245749738
$6,505.12
in general payments reported to CMS, 2019-2025
20 companies · $2,628 in 2025
The $2,628 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $814 · 2023: $883 · 2024: $1,746 · 2025: $2,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,256.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,404.11 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,000.38 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $842.26 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $614.65 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $529.46 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $525.99 | 2022-2025 | |
| Axsome Therapeutics, INC. | $437.12 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $403.62 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $189.51 | 2021-2025 | Spravato |
| Indivior INC. | $157.04 | 2021-2025 | Sublocade, Perseris |
| Corium, LLC | $101.01 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $64.31 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $49.44 | 2021 | |
| Sunovion Pharmaceuticals INC. | $47.91 | 2021 | |
| Ironshore Pharmaceuticals INC. | $38.03 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.21 | 2025 | Cobenfy |
| Braeburn INC. | $22.57 | 2025 | Brixadi |
| Noven Therapeutics, LLC | $13.89 | 2024 | Xelstrym |
| Lundbeck LLC | $13.82 | 2025 | Rexulti |
| Amgen INC. | $13.79 | 2023 | Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Ocampo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.